The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin disease (CAD), are now expected in early 2025, the company has announced. That trial is testing a new tablet formulation of the oral therapy in people with CAD. Earlier this…
Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…
Decisions about cold agglutinin disease (CAD) treatment need to be made on a case-by-case basis, considering each patient’s specific situation, a pair of scientists in Italy argued in a review study. The scientists reviewed available and up-and coming treatment options for CAD, giving advice for how best to employ…
Obinutuzumab, a B cell-depleting medication approved for certain blood cancers, was effective for controlling primary cold agglutinin disease (CAD) in a woman in China, according to a case study. The treatment “shows a promising role in CAD which might [warrant] further investigation,” researchers wrote in the case study, “…
Enjaymo (sutimlimab), the only approved treatment for cold agglutinin disease (CAD), needs to be about 80% cheaper or be used for a maximum limit of 1.5 years to meet conventional thresholds for cost-effectiveness in the U.S. That’s according to a cost-effectiveness analysis that was based on data from…
A step-by-step process is needed to accurately diagnose cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA), according to a report. This process involves the detection of blood cell destruction, establishing whether this is due to an immune attack, and finally zeroing in on the specific…
Initial results from a planned proof-of-concept clinical trial testing Annexon Biosciences’ treatment candidate ANX1502 in people with cold agglutinin disease (CAD) are expected in the second half of the year. “We anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year,” Douglas Love, president…
Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped the clinical development of the experimental therapy pegcetacoplan for cold agglutinin disease (CAD). The decision, which includes discontinuing a Phase 3 clinical trial of the therapy in adults, was based on a realignment of the companies’ priorities in…
Certain variations in genes that encode cytokines — signaling molecules involved in immune responses — may predispose people toward the development of cold agglutinin disease (CAD), a new study suggests. The study, “Cytokine polymorphisms in patients with autoimmune hemolytic anemia,” was published in Frontiers in…
A single infusion of one of two doses of SAR445088 — Sanofi’s potential successor to Enjaymo (sutimlimab-jome) — was well-tolerated by people with cold agglutinin disease (CAD) in a small Phase 1b clinical trial. The experimental therapy, also known as riliprubart, appeared to work as expected, with…
Get regular updates to your inbox.